Definium Therapeutics, Inc. (DFTX) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount

Definium Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount

Definium Therapeutics, Inc. (DFTX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $1.25 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Expense Statement › Income Tax

us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26

• Definium Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $1.25M, a 37.41% decline from fiscal 2023.
• Definium Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $2.00M, a 15.59% increase from fiscal 2022.
• Definium Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $1.73M, a 29.62% decline from fiscal 2021.
• Definium Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was $2.46M.